120
Views
2
CrossRef citations to date
0
Altmetric
Clinical Trial Report

SABA Overuse in Russia – Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study

ORCID Icon, ORCID Icon, , , , , ORCID Icon & show all
Pages 371-379 | Published online: 24 Mar 2022

References

  • Global Initiative for Asthma - GINA. 2019 GINA main report. Available from: https://ginasthma.org/gina-reports/. Accessed June 8, 2020.
  • O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? J Respir Eur. 2017;50(3). doi:10.1183/13993003.01103-2017
  • Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–407. doi:10.1016/j.anai.2012.08.014
  • Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med. 1994;149(3):604–610. doi:10.1164/ajrccm.149.3.8118625
  • Suissa S, Blais L, Ernst P. Patterns of increasing β-agonist use and the risk of fatal or near-fatal asthma. J Respir Eur. 1994;7(9):1602–1609. doi:10.1183/09031936.94.07091602
  • Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β 2 -agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. J Respir Eur. 2020;55(4):1901872. doi:10.1183/13993003.01872-2019
  • Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe. 2015;11(1):15–24. doi:10.1183/20734735.008914
  • O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129–136. doi:10.1164/rccm.200407-884OC
  • Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide – formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030. doi:10.1056/nejmoa1901963
  • O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876. doi:10.1056/NEJMoa1715274
  • Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide – formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–1887. doi:10.1056/nejmoa1715275
  • Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. J Respir Eur. 2019;53(6):1901046. doi:10.1183/13993003.01046-2019
  • Cabrera CS, Nan C, Lindarck N, Beekman MJ, Arnetorp S, van der Valk RJP. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2 -agonist use in asthma. J Respir Eur. 2020;55(2):1901858. doi:10.1183/13993003.01858-2019
  • SABINA: an overview of short-acting β2-agonist use in asthma in European countries. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089727/. Accessed November 29, 2020.
  • Gibson P, Henry D, Francis L, et al. Association between availability of non-prescription β2 agonist inhalers and undertreatment of asthma. J Med Br. 1993;306(6891):1514–1518. doi:10.1136/bmj.306.6891.1514
  • Azzi EA, Kritikos V, Peters MJ, et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey. BMJ Open. 2019;9(8):e028995. doi:10.1136/bmjopen-2019-028995
  • Nelson HS, Weiss ST, Bleecker EK, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. In: Chest. Vol. 129. American College of Chest Physicians;2006:15–26. doi:10.1378/chest.129.1.15
  • Aisanov Z, Avdeev S, Arkhipov V, Belevsky A. SYmbicort given as needed in mild asthma (SYGMA study): a retrospective subanalysis of the Russian population. J Asthma. 2021;1–9. doi:10.1080/02770903.2021.1892753
  • Paris J, Peterson EL, Wells K, et al. Relationship between recent short-acting β-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol. 2008;101(5):482–487. doi:10.1016/S1081-1206(10)60286-4
  • Anis AH, Lynd LD, Wang XH, et al. Double trouble: impact of inappropriate use of asthma medication on the use of health care resources. CMAJ. 2001;164(5):625–631.
  • Nasser S. An imperfect “PAST” lessons learned from the National Review of Asthma Deaths (NRAD) UK. Respir Res. 2016;17(1). doi:10.1186/s12931-016-0393-9